Sungkyunkwan University · Medicine
Professor Jiyun Lee's research lab specializes in translational oncology, focusing on targeted therapy and immunotherapy for advanced non-small cell lung cancer (NSCLC) and breast cancer. The lab investigates novel molecular mechanisms of resistance to targeted agents such as EGFR and ALK/ROS1 tyrosine kinase inhibitors, with particular emphasis on overcoming central nervous system metastases and drug resistance. It also explores ethnic differences in treatment response and immune-related adverse events, especially in Asian populations, to optimize personalized therapy. The lab is actively involved in evaluating next-generation targeted therapies like lorlatinib and trastuzumab deruxtecan in biomarker-selected patients.
Figures are computed from collected data and may differ slightly.
Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody-drug conjugate, has shown significant clinical benefits in HER2+ metastatic breast cancer patients. In the phase 2 DESTINY-Breast01 trial, T-DXd demonstrated an objective response of 60.9% and median progression-free survival of 16.4 months, laying the foundation for accelerated approval in HER2+ metastatic breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. Moreover, T-DXd e
Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms.
Immunotherapy, especially immune checkpoint inhibitors, has revolutionized the treatment of non-small cell lung cancer. However, data on ethnic differences in response to these treatments are still lacking. We reviewed the currently available clinical data on immune checkpoint inhibitors and analyzed the ethnic difference in terms of treatment efficacies and side effects. Despite different epidemiology, genetic susceptibility and molecular profiles, Asian lung cancer patients demonstrated compar
Given the likelihood of RET-rearranged NSCLC progressing to intracranial metastases and the absence of apparent clinical benefit of currently available targeted or immunotherapeutic agents, development of novel treatment with higher selectivity and better penetration of the blood-brain barrier remains a priority.
This study is the first to report that lorlatinib is an important novel therapeutic option for Asian patients who have advanced NSCLC harboring ALK/ROS1 mutations whose disease progressed during treatment with first- and second-generation TKIs.
Whereas treatment outcomes with conventional anticancer therapy are reasonable and immunotherapy looks promising, the unmet need remains high for patients with <i>KRAS</i>-mutated NSCLC in Asia, underscoring the need for novel therapeutic approaches.
This study includes the largest set of integrated genomic data analyzing Asian patients with melanoma treated with immunotherapy. BRAF <sup>V600</sup> and KIT mutational statuses were not associated with response or survival, and high NLR was a strong predictor of poor response to and survival with anti-PD-1 therapy.
Open papers in the app to read, cite, and organize with AI.
